| Name | Healthwin |
|---|---|
| Location | 20531 Darden Rd, South Bend, Indiana |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 153 |
| Occupancy Rate | 68.89% |
| Medicare ID (CCN) | 155153 |
| Legal Business Name | St. Clair Darden Health System Inc |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1093750119 |
| Organization Name | ST. CLAIR DARDEN HEALTH SYSTEM INC |
| Doing Business As | HEALTHWIN |
| Address | 20531 Darden Rd, South Bend, IN 46637 |
| Phone Number | 574-272-0100 |
News Archive
Within a few years, a new generation of easy-to-use blood-thinning drugs will likely replace Coumadin for patients with irregular heartbeats who are at risk for stroke, according to a journal article by Loyola University Medical Center physicians.
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).
Pharmacyclics, Inc. today announced results from a Phase I study of its novel orally administered Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, in patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukemia (CLL) and Waldenstroms Macroglobulinemia (WM). These data are being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place this week in Chicago, IL.
Researchers find that popular websites share search data with advertisers and other third parties. The National Security Agency is tracking your phone calls. And online snoops may be keeping tabs on your Internet health searches, too.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Within a few years, a new generation of easy-to-use blood-thinning drugs will likely replace Coumadin for patients with irregular heartbeats who are at risk for stroke, according to a journal article by Loyola University Medical Center physicians.
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).
Pharmacyclics, Inc. today announced results from a Phase I study of its novel orally administered Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, in patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukemia (CLL) and Waldenstroms Macroglobulinemia (WM). These data are being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place this week in Chicago, IL.
Researchers find that popular websites share search data with advertisers and other third parties. The National Security Agency is tracking your phone calls. And online snoops may be keeping tabs on your Internet health searches, too.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 18.29 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.06 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 72.78 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.82 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.54 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.28 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.41 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 6.56 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 99.32 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.97 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 25.65 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 15.52 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.57 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.88 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 63.93 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 93.81 | 82.93 |
News Archive
Within a few years, a new generation of easy-to-use blood-thinning drugs will likely replace Coumadin for patients with irregular heartbeats who are at risk for stroke, according to a journal article by Loyola University Medical Center physicians.
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).
Pharmacyclics, Inc. today announced results from a Phase I study of its novel orally administered Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, in patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukemia (CLL) and Waldenstroms Macroglobulinemia (WM). These data are being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place this week in Chicago, IL.
Researchers find that popular websites share search data with advertisers and other third parties. The National Security Agency is tracking your phone calls. And online snoops may be keeping tabs on your Internet health searches, too.
› Verified 2 days ago
Cardinal Nursing And Rehabilitation Center Location: 1121 E Lasalle Ave, South Bend, Indiana 46617 Phone: (574) 287-6501 | |
Signature Healthcare Of South Bend Location: 52654 N Ironwood Rd, South Bend, Indiana 46635 Phone: (574) 277-8710 | |
West Bend Nursing And Rehabilitation Location: 4600 W Washington Ave, South Bend, Indiana 46619 Phone: (574) 282-1294 | |